HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma— Their distribution in relation to prognosis

Furihata, Mutsuo; Ohtsuki, Yuji; Ido, Eiji; Iwata, Jun; Shinmoto, Hiroshi; Araki, Keijirou; Ogoshi, Shohei; Ohmori, Katsusuke

doi:10.1007/bf02890444

Cited by 56 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dense infiltration of 5100+DCs has recently been demonstrated to be correlated significantly with a favorable prognosis in patients with esophageal SCCs (Matsuda et al 1990). Moreover, we have recently reported on the characteristics and prognostic significance of not only 5100+DC, but also DRDC in 59 patients with esophageal SCCs (Furihata et al 1992). TILs are generally thought to be involved in host resistance to tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Single immunoperoxidase staining for each antibody was performed by the avidin-biotin complex (ABC) method with an streptavidin biotin complex peroxidase (SAB-PO) kit (Histofine SAB-PO kit; Nichirei Inc., Tokyo), as described previously (Furihata et al 1992). In order to demonstrate the relationship between DWDCs and TILs in the same section, we also performed double immunostaining as follows.…”

Section: Immunohistochemical Stainingmentioning

confidence: 99%

“…Then the cell numbers were averaged and they are summarized in Table 2. From the number of DR+DC and UCHL1-T cells, according to our previous paper (Furihata et al 1992), tumors were classified into two groups, i.e., few ; (0-9 cells/HPF) and numerous (> 10 cells/HPF). Thus, the subjects could be divided into the following four groups : "numerous" DR+DC and "numerous" UCHL 1 -T (Group 1) , "numerous" DR+DC and "few" UCHL1-T (Group 2), "few" DR+DC and "numerous" UCHL1-T (Group 3) and "few" DR+ DC and "few" UCHL1-T (Group 4) ( Table 3).…”

Section: Evaluation Of Dr+dc and Til Numbersmentioning

confidence: 99%

“…Our investigations have revealed three immunohistochemicallly different DC types in human esophageal squamous cell carcinoma (SCC), i.e., S-100-negative but HLA-DR-positive DCs (5100-DR+DCs), S-100-positive but HLA-DR-negative DCs (5100+DR-DCs) and double-positive DCs (5100+DR+DCs) (Furihata et al 1992).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of Simultaneous Infiltration of HLA-DR-Positive Dendritic Cells and Tumor Infiltrating Lymphocytes into Human Esophageal Carcinoma.

Furihata

Ohtsuki

Shinmoto

et al. 1993

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Immunohistochemical Stainingmentioning

confidence: 99%

Section: Evaluation Of Dr+dc and Til Numbersmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Significance of Simultaneous Infiltration of HLA-DR-Positive Dendritic Cells and Tumor Infiltrating Lymphocytes into Human Esophageal Carcinoma.

Furihata

Ohtsuki

Shinmoto

et al. 1993

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

“…It has been reported that there is a positive correlation between the number of DCs in tumors and the suppression of the tumor growth, suggesting that DCs infiltrating tumors suppress the tumor growth (2)(3)(4). Based on these findings, anti-tumor therapies using DCs have been tried experimentally and clinically with some success in terms of the suppression of tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor effects of fusion cells of type 1 dendritic cells and Meth A tumor cells using hemagglutinating virus of Japan-envelope

Yanai

Adachi²,

Fuijisawa³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. It has been reported that the fusion cells of dendritic cells (DCs) and tumor cells have anti-tumor effects. In this experiment, we examined the anti-tumor effects of fusion cells of bone marrow-derived DC type 1 (DC1) and irradiated tumor cells using a newly commercially available hemagglutinating virus of Japan-envelope (HVJ-E) after cell fusion, in a mouse model. To induce DC1, bone marrow cells (BMCs) from BALB/c mice were cultured with GM-CSF, IL-12 and IFN-Á. BMC-derived DC1 were fused with 20-Gy-irradiated Meth A cells (BALB/c-derived fibrosarcoma) using HVJ-E. We subcutaneously injected: i) the BMC-derived DC1, or ii) the fusion cells of the DC1 and the irradiated Meth A cells, into Meth A-bearing BALB/c mice. The injection of only DC1 showed a moderate anti-tumor effect, as we previously described. However, the fusion cells were more effective in not only suppressing tumor growth but also prolonging survival. These results suggest that the fusion cells of DC1 and the irradiated tumor cells using HVJ-E were more effective in tumor suppression than DC1 alone.

show abstract

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice

et al. 1998

View full text Add to dashboard Cite

Background and Objectives: Dendritic cells (DC) pulsed in vitro with a variety of antigens have proved effective in producing specific antitumor effects in vivo. Experimental evidence from other laboratories has confirmed that shared antigens can be encountered in histologically distinct tumors. In our experiments, we set out to evaluate the immunotherapeutic potential of vaccines consisting of DC pulsed with MCA‐106 fibrosarcoma or B16 melanoma cell lysates and to determine whether a cross‐reactivity exists between the two tumors. Methods DC were prepared from the bone marrow of C57BL/6 (B6) mice by culturing progenitor cells in murine granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). They were separated into three equal groups and were either pulsed with B16 melanoma cell lysates (BDC), pulsed with tumor extract from the syngeneic fibrosarcoma MCA‐106 (MDC), or left unpulsed (UDC). DC were then used to immunize three groups of mice, with all mice receiving two weekly intravenous (IV) doses of 1 × 106 DC from their respective preparations on days −14 and −7. A fourth group of control mice were left untreated. On day 0, all mice were challenged with subcutaneous injections of 1 × 105 B16 and 1 × 105 MCA tumor cells, administered in the left and right thighs, respectively. After the inoculations, the mice were monitored closely with respect to tumor growth and survival. Results The MDC mice developed specific cellular immunity directed against not only MCA‐106 tumor cells, but also against B16 melanoma, as measured through chromium‐release assays of splenocyte preparations, while remaining ineffective at killing both L929 fibroblasts and CT26 tumor cells. By day 30 after tumor inoculations, control mice manifested the largest B16 tumor volumes at a mean of 2185 mm3, followed by the UDC, MDC, and BDC groups at 92 mm3 (P = 0.00008), 3 mm3 (P = 0.000002), and 2 mm3 (P = 0.00004), respectively. The survival data mirrored this pattern, with control animals displaying the shortest mean survival time (37.1 ± 4.0 days), followed by UDC (44.8 ± 6.6), MDC (56.2 ± 14.7), and BDC (56.4 ± 18.3) animals. No significant differences were noted between MCA‐106 and B16 cell lysate‐pulsed DC vaccines with respect to their abilities to inhibit B16 tumor growth and to prolong survival. These findings were confirmed using a B16 pulmonary metastasis model. Likewise, vaccination with interferon‐γ gene‐modified MCA‐106 tumor cells was shown to be effective at protecting against a subsequent subcutaneous B16 tumor challenge in 3 of 4 mice observed. Conclusions These results demonstrate that immunization with antigen‐pulsed DC confers cellular immunity, retards tumor growth, and prolongs the survival of tumor‐challenged mice. The ability of MCA‐106 cell lysate‐pulsed DC vaccines to inhibit the growth of subcutaneous B16 tumors also suggests the presence of shared tumor‐associated antigens between these two histologically distinct tumors. J. Surg. Oncol. 1998;68:79–91. © 1998 Wiley‐Liss, Inc.

show abstract

HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma— Their distribution in relation to prognosis

Cited by 56 publications

References 16 publications

Prognostic Significance of Simultaneous Infiltration of HLA-DR-Positive Dendritic Cells and Tumor Infiltrating Lymphocytes into Human Esophageal Carcinoma.

Prognostic Significance of Simultaneous Infiltration of HLA-DR-Positive Dendritic Cells and Tumor Infiltrating Lymphocytes into Human Esophageal Carcinoma.

Anti-tumor effects of fusion cells of type 1 dendritic cells and Meth A tumor cells using hemagglutinating virus of Japan-envelope

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice

Contact Info

Product

Resources

About